Eagle Point Credit Co (ECC): Management’s unaudited estimate of the range of the net asset value per common share as of September 30, 2026 was between $4.12 and $4.22

Eagle Point Credit Co (ECC) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. Management’s unaudited estimate of the range of the net asset value per common share as of September 30, 2026 was between $4.12 and $4.22. In addition, for the quarter ended September 30, 2026, management’s unaudited estimate of the range of the Company's

Event · Guidance
Metric
net asset value per common share
Period
as of September 30, 2026
New
between $4.12 and $4.22

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 14, 2026, 12:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ECC
Neutral
medium confidence
Mentioned
$ECC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ECCNeutralLow
01

Why it matters

The filing provides the first public estimate of the fund’s valuation for the quarter, offering a data point for price assessment.

02

Market read

Primary disclosure of NAV guidance for a small‑cap credit fund; modest trading relevance.

03

What to watch

Potential impact of upcoming credit market conditions on the fund’s asset performance.

Relevance 5/10Novelty 5/10Timing: today

Background

Eagle Point Credit Co filed an 8‑K filing disclosing its unaudited net asset value per share and net investment income for Q3 2026.

Company-level read

Ticker impact

$ECCNeutralMedium confidence
Context

SEC 8‑K reports management’s unaudited NAV estimate of $4.12‑$4.22 per share for Q3 2026.

Expected impact

possible modest upside if market views the NAV as higher than prior expectations, or pressure if seen as lower.

Evidence & confidence

NAV guidance is new information but the absolute dollar range is modest for a small‑cap BDC, limiting material impact.

Market effects

Limited; may slightly affect other BDCs as investors compare NAV guidance.

None

None

Counterpoint

Investors could view the NAV range as a buying opportunity if they expect higher future earnings.

Key entities

  • Eagle Point Credit Co

    Closed‑end credit fund listed on NYSE under ticker ECC.

Related articles

$ECCMed

Eagle Point Q3 2026 slides: private credit shift drives diversification

Eagle Point Credit Company (ECC) reported Q3 2026 results, with net investment income rising to $0.31 per share. The company is shifting toward private credit, now 38% of its portfolio. NAV declined 8% to $4.17 per share. ECC trades at $2.295, up 7.75% from the previous close. Management declared monthly distributions of $0.06 per share for early 2027. The company's AUM stands at $14 billion.

$BRFHMed

Barfresh Manufacturing Recovery Drives Margins – Quarterly Update Report

Barfresh Manufacturing (BRFH) reported 3Q26 revenue of $5.8M, up 37% y/y, with gross margin rebounding to 20.9% from negative 3.2% q/q. Core margins reached 34%, and adjusted EBITDA neared breakeven. The company added 50 Ohio school districts and reactivated a major Florida district. 2026 revenue guidance was revised to $20M-$22M, with Defiance facility commissioning targeted for early to mid-2027. BRFH trades at a 75% discount to peers, offering potential rerating as growth accelerates.

$PYXSHighAI 9/10

Pyxis reports updated phase 1 data for cancer drug candidate

Pyxis Oncology (PYXS) reported updated Phase 1 data for micvotabart pelidotin, showing a 39% response rate in 33 patients with recurrent/metastatic head and neck cancer. The study reported a median progression-free survival of 6.7 months and a 94% disease control rate. Pyxis plans to initiate a Phase 3 trial in mid-2027 and expects to release more mature overall survival data in the first half of 2027.

$PYXSMedAI 8/10

Pyxis Oncology (PYXS) Reports 39% Confirmed MICVO Response Rate

Pyxis Oncology (PYXS) reported updated Phase 1 data for MICVO, showing a 39% confirmed response rate, 9.2-month median response duration, and 6.7-month median PFS in 33 patients. The company plans to start a global Phase 3 trial in mid-2027. The data is not yet confirmatory, and further results are expected in early 2027.